Rationale and applications of lipids as prodrug carriers.
about
Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.Quantifying exploratory low dose compounds in humans with AMS.Synthesis and Biological Evaluation of Novel Phosphatidylcholine Analogues Containing Monoterpene Acids as Potent Antiproliferative AgentsIsoprenoid-phospholipid conjugates as potential therapeutic agents: Synthesis, characterization and antiproliferative studiesImproving nucleoside analogs via lipid conjugation: Is fatter any better?A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery.Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activityNew non-oral drug delivery systems for Parkinson's disease treatment.Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches.Lipid-based drug carriers for prodrugs to enhance drug delivery.Lipid-Drug Conjugate for Enhancing Drug Delivery.Bioreversible derivatives of phenol. 1. The role of human serum albumin as related to the stability and binding properties of carbonate esters with fatty acid-like structures in aqueous solution and biological media.Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin.Quantitative analysis of the effect of triglyceride alkyl-chain length on the partitioning of highly lipophilic compounds to the mesenteric lymph in intestinal cells.
P2860
Q34701454-A662EA67-AB93-4E07-89BC-F83401355FF7Q34708648-BE0CC2CC-83A4-4AEB-9020-C07A94CEBDBBQ36054396-36EBDC96-5573-4E9C-A45A-081143D8ECD8Q36280086-7077B434-9631-48B0-9436-E914D277406FQ36706248-6B499DC1-89B6-460A-AAE0-21B03B9DA5EBQ36742881-2319D305-039B-4D9D-B3CF-8820CDF546E5Q37103787-97B51419-F4DF-49CF-B843-11ED1FA42FBBQ37840165-93B94BAF-16D6-4A9F-90A9-309580984549Q38136249-8A21D251-95D3-4A42-8C97-6EBE58CFB83FQ38255590-4D55899E-28A6-4DBB-9791-9925B051CD7FQ39083391-5805E7DB-0246-461F-B059-D36309D48587Q46917782-0A98E42E-5F91-4D9C-B1BD-E80C6535E9EFQ49103683-D8BE1E12-C83E-4CF9-B385-46CD42F6FD8CQ51158545-A6CDBB42-8CE4-43C0-9114-25CB1046D96A
P2860
Rationale and applications of lipids as prodrug carriers.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Rationale and applications of lipids as prodrug carriers.
@ast
Rationale and applications of lipids as prodrug carriers.
@en
Rationale and applications of lipids as prodrug carriers.
@nl
type
label
Rationale and applications of lipids as prodrug carriers.
@ast
Rationale and applications of lipids as prodrug carriers.
@en
Rationale and applications of lipids as prodrug carriers.
@nl
prefLabel
Rationale and applications of lipids as prodrug carriers.
@ast
Rationale and applications of lipids as prodrug carriers.
@en
Rationale and applications of lipids as prodrug carriers.
@nl
P1476
Rationale and applications of lipids as prodrug carriers.
@en
P2093
Lambert DM
P304
P356
10.1016/S0928-0987(00)00161-5
P407
P478
11 Suppl 2
P577
2000-10-01T00:00:00Z